www.TheFinancialMarketingGroup.com
Followers | 59 |
Posts | 2,197 |
Boards Moderated | 4 |
Alias Born | 04/28/2019 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Long or short INCYTE corp ? Move coming soon.
Fundamentally nothing much has changed in INCY recently but technically the stock is reaching a point of decision, is the correction? can we go higher? we are biased towards a break higher as indicators are improving while the price gets squeezed between they 100 and 200ma. The $82 region may be a good area to look for a long on a break from converging trendlines , while also clearing the MA's resistance, a bounce of the bottom Bollinger Band is also anticipated.
Long or short INCYTE corp ? Move coming soon.
Fundamentally nothing much has changed in INCY recently but technically the stock is reaching a point of decision, is the correction? can we go higher? we are biased towards a break higher as indicators are improving while the price gets squeezed between they 100 and 200ma. The $82 region may be a good area to look for a long on a break from converging trendlines , while also clearing the MA's resistance, a bounce of the bottom Bollinger Band is also anticipated.
$CI ANTHEM AND MEDICARE HAVE PRODUCED A DARK CLOUD ABOVE CIGNA
From a fundamental perspective, this entire sector will be used as a pawn within the political parties to gain favor with the electorate until after the 2020 election, that is quite a while to wait for a safe entry point or maybe not. Cigna is also embroiled in a long suffering court case with NYSE:ANTM claiming THAT ANTM should pay compensation of $16 billion for the botched takeover in 2015. IF CI was to win the case it would be extraordinary but most likely they will be awarded the break up of fee of $1.84 billion.
From a technical point of view the chart is becoming quite interesting and suggesting a entry point may be on the way. Please consult the chart for analysis but a break and possible retest of the trend-line(blue) would be a good buy signal.
$CI ANTHEM AND MEDICARE HAVE PRODUCED A DARK CLOUD ABOVE CIGNA
From a fundamental perspective, this entire sector will be used as a pawn within the political parties to gain favor with the electorate until after the 2020 election, that is quite a while to wait for a safe entry point or maybe not. Cigna is also embroiled in a long suffering court case with NYSE:ANTM claiming THAT ANTM should pay compensation of $16 billion for the botched takeover in 2015. IF CI was to win the case it would be extraordinary but most likely they will be awarded the break up of fee of $1.84 billion.
From a technical point of view the chart is becoming quite interesting and suggesting a entry point may be on the way. Please consult the chart for analysis but a break and possible retest of the trend-line(blue) would be a good buy signal.
$MGM Chart is setting up bullish in MGM, may pullback a little.
When scanning for a investment, many factors come into play, two of which are unusual options action and insider buying, both are very significant tells as to the direction in which the stock is going, that is why MGM looks very interesting at this level. Directors have been loading up in shares in a massive way and options traders have been making big bets a impending positive move higher. The sector as a whole has become very bullish as speculation is rampant regarding mergers and takeovers. Watch this space and expect a little pullback here for the bullish channel to form and break to the upside.
AVERAGE ANALYSTS PRICE TARGET $33
AVERAGE ANALYSTS RECOMMENDATION
COMPANY PROFILE
MGM Resorts International is a holding company, which engages in the ownership and operations of casino resorts. The firm's casino resorts offer gaming, hotel, convention, dining, entertainment, retail, and other resort amenities. It operates through the following business segments: Las Vegas Strip Resorts, Regional Operations and MGM China. The Las Vegas Strip Resorts segment consists of the following casino resorts: Bellagio, MGM Grand Las Vegas, Mandalay Bay, The Mirage, Luxor, New York-New, Excalibur, Park MGM , and Circus Las Vegas. The Regional Operations segment consists of the following casino resorts: MGM Grand Detroit in Detroit, Michigan; Beau Rivage in Biloxi, Mississippi; Gold Strike Tunica in Tunica, Mississippi; Borgata in Atlantic City, New Jersey; MGM National Harbor in Prince George's County, Maryland; and MGM Springfield in Springfield, Massachusetts. The MGM China segment consists of MGM Macau and MGM Cotai. The company was founded by Kerkor Kerkorian on January 29, 1986 and is headquartered in Las Vegas, NV.
$MGM Chart is setting up bullish in MGM, may pullback a little.
When scanning for a investment, many factors come into play, two of which are unusual options action and insider buying, both are very significant tells as to the direction in which the stock is going, that is why MGM looks very interesting at this level. Directors have been loading up in shares in a massive way and options traders have been making big bets a impending positive move higher. The sector as a whole has become very bullish as speculation is rampant regarding mergers and takeovers. Watch this space and expect a little pullback here for the bullish channel to form and break to the upside.
AVERAGE ANALYSTS PRICE TARGET $33
AVERAGE ANALYSTS RECOMMENDATION
COMPANY PROFILE
MGM Resorts International is a holding company, which engages in the ownership and operations of casino resorts. The firm's casino resorts offer gaming, hotel, convention, dining, entertainment, retail, and other resort amenities. It operates through the following business segments: Las Vegas Strip Resorts, Regional Operations and MGM China. The Las Vegas Strip Resorts segment consists of the following casino resorts: Bellagio, MGM Grand Las Vegas, Mandalay Bay, The Mirage, Luxor, New York-New, Excalibur, Park MGM , and Circus Las Vegas. The Regional Operations segment consists of the following casino resorts: MGM Grand Detroit in Detroit, Michigan; Beau Rivage in Biloxi, Mississippi; Gold Strike Tunica in Tunica, Mississippi; Borgata in Atlantic City, New Jersey; MGM National Harbor in Prince George's County, Maryland; and MGM Springfield in Springfield, Massachusetts. The MGM China segment consists of MGM Macau and MGM Cotai. The company was founded by Kerkor Kerkorian on January 29, 1986 and is headquartered in Las Vegas, NV.
$RH INVESTORS TAKE A COMFY SEAT, 28% POP, ON GREAT GUIDANCE.
This was a quarter that many were worried about, thus the decline pre earnings , the cloud of China trade has scared investors away. The earnings were a blowout rather than a beat, with adjusted earnings of $1.85 per share rather than the $1.53 expected, while revenue also beat by $14million.
RH also addressed the rising trade tensions between Washington and Beijing saying that it doesn't believe the "current trade climate will impair our ability to achieve our stated financial goals." The company has worked hard on sourcing, negotiating and pricing to maintain margins while not effecting sales.
The 28% jump today is fantastic but it is a missed opportunity, don't fret this stock will go back to the $160 level and a all time high soon, a opportunity above the 200ma or the gap fill level will still reward you with a + 20% return.
$RH INVESTORS TAKE A COMFY SEAT, 28% POP, ON GREAT GUIDANCE.
This was a quarter that many were worried about, thus the decline pre earnings , the cloud of China trade has scared investors away. The earnings were a blowout rather than a beat, with adjusted earnings of $1.85 per share rather than the $1.53 expected, while revenue also beat by $14million.
RH also addressed the rising trade tensions between Washington and Beijing saying that it doesn't believe the "current trade climate will impair our ability to achieve our stated financial goals." The company has worked hard on sourcing, negotiating and pricing to maintain margins while not effecting sales.
The 28% jump today is fantastic but it is a missed opportunity, don't fret this stock will go back to the $160 level and a all time high soon, a opportunity above the 200ma or the gap fill level will still reward you with a + 20% return.
Its really hard to be positive on NIO, But I've tried. Believer
We all know what a painful ride this has been for believers, we have looked at the chart every day hoping for a reversal, unfortunately the news flow, political and trade uncertainty, economic slowdown and of course poor earnings reports have all added fuel to the already burning fire. The stock looks destined to hit the $2 level and it really is the last stand in our opinion, it will soon be at the mercy of pump and dump penny stock day traders, where green candles can't be trusted. We have tried to pick the positives from the chart, so please have a good look and if you agree please give us a like and share and share your opinion below, it would be much appreciated as we are believers in this stock and hope that it turns around soon but $2 is our key level.
Comments like this have not helped the cause,
"Looking ahead to the second quarter, we expect an even more challenging sales environment and anticipate overall sequential demand and deliveries to decrease, as competition continues to accelerate and the general automobile market in China remains muted… Against this backdrop, NIO is focusing on rolling out our ES6 nationwide, and at the same time, improving overall network utilization and operating efficiencies."
Its really hard to be positive on NIO, But I've tried. Believer
We all know what a painful ride this has been for believers, we have looked at the chart every day hoping for a reversal, unfortunately the news flow, political and trade uncertainty, economic slowdown and of course poor earnings reports have all added fuel to the already burning fire. The stock looks destined to hit the $2 level and it really is the last stand in our opinion, it will soon be at the mercy of pump and dump penny stock day traders, where green candles can't be trusted. We have tried to pick the positives from the chart, so please have a good look and if you agree please give us a like and share and share your opinion below, it would be much appreciated as we are believers in this stock and hope that it turns around soon but $2 is our key level.
Comments like this have not helped the cause,
"Looking ahead to the second quarter, we expect an even more challenging sales environment and anticipate overall sequential demand and deliveries to decrease, as competition continues to accelerate and the general automobile market in China remains muted… Against this backdrop, NIO is focusing on rolling out our ES6 nationwide, and at the same time, improving overall network utilization and operating efficiencies."
GDET is our new subpenny alert w/ a 6-cent price target.
=====================
GDET ( GD Entertainment & Technology, Inc.)
Alert Price: $0.0069
Chart Analysis
Goldman Price Target: $0.06
Goldman Small Cap Research Report
Website | Recent News
Ecommerce: http://www.thegreeneryco.com
========================
Members,
Earlier today we promised you an explosive subpenny alert with massive upside potential.
In case you forgot, our last subpenny alert broke out for over +230% in profits!
You'll be happy to know, that our latest subpenny alert has the potential to breakout for all that and more.
In fact, the company has an upside of +769% from today's subpenny alert price.
Please turn your immediate attention to GD Entertainment And Technology (OTC: GDET).
GDET is the Top Pure Play on 3 of the Fastest Growing Industries
GDET, focuses on high growth industries to fulfill a diverse selection of premium products nationwide. The company currently has three subsidiaries: DreamCard, HyperDigital Technologies, and The Greenery. DreamCard allows users to create a customizable debit or credit card using its state-of the-art online platform Dreamcard. cc HyperDigital Technologies is the Cryptocurrency ATM sector of GDET and aims to secure multiple MSB, money services business, licenses in order to host ATM units throughout the country. The Greenery is a new subsidiary slated to launch a broad offering of hemp-derived CBD products.
Subpenny Stocks = Big Moves
GDET has a history of seeing rapid gains in the short term. Just last month it hit over a penny when it was as low as $0.0055 at the end of April. The gain here was 100% in just a few days.
Earlier this year shares shares were as low as $0.0027 at the end of February and then hit $0.0229 in March for a Gain of Nearly 750% in Just a Few Weeks!
We are banking on another big move from GDET tomorrow, as both the crypto and cannabis sectors are heating up.
We see no reason why GDET can't once again move beyond $0.01.
Especially since the Company has recently made some big announcements that are sure to grab the attention of the Street.
At the end of last month GDET announced that it had completed its migration to a new cryptocurrency mining pool and is running at full capacity.
The new mining pool is also fully integrated with major cryptocurrency exchanges, which means the user can seamlessly send and trade the cryptocurrency reward payouts in real time market conditions. With lesser transaction and payout times/restrictions, the flexibility of converting the cryptocurrency can become more favorable.
The $275 billion cryptocurrency market is continuing to experience a serious rally with bitcoin once again moving past $8,000.
GDET CEO Anil Idnani commented, “I am very proud to announce that my team was able to complete this migration on every one of our machines without any difficulties. We are already experiencing a higher total operating hashrate than the previous mining pool our machines were integrated with. The upgrade in firmware and new mining pool allows the operation to run at full capacity during this crypto rally and I look forward to seeing what new barriers Bitcoin and cryptocurrencies break next.”
The Greenery is updating their e-commerce platform to include upgraded features such as live chat support, wholesaler login, bulk purchase + subscription order capabilities and much more. In addition to its enhanced retail content, the website will provide product education made available free to all visitors.
The Greenery has placed a purchase order for CBD product, sourced by its preferred US manufacturer. The Company recently announced that The Greenery would introduce a cosmeceutical and active lifestyle collection to its product line. This purchase order will include quantities of the honey hemp products, gummies, and pet wellness collection. In addition to fulfilling the new lines, several SKUs of The Greenery’s best-selling product have also been reordered including the highly-acclaimed CBD-infused hydration face mask.
The above actions by GDET could result in a massive influx of revenue in the very near future.
That being said, we have a feeling that GDET is going to be our next subpenny alert to deliver triple digit gains.
But don't just take our word for it, Goldman Small Cap Research recently slapped a $0.06 price target on this $0.0069 stock.
We just did the quick math, and that's an upside of over +769%!
About GD Entertainment and Technology
GD Entertainment & Technology, also known as GDET, focuses on high growth industries to fulfill a diverse selection of premium products nationwide. The company currently has three subsidiaries: DreamCard, HyperDigital Technologies, and The Greenery. DreamCard allows users to create a customizable debit or credit card using its state-of the-art online platform Dreamcard. cc HyperDigital Technologies is the Cryptocurrency ATM sector of GDET and aims to secure multiple MSB, money services business, licenses in order to host ATM units throughout the country. The Greenery is a new subsidiary slated to launch a broad offering of hemp-derived CBD products.
Company Highlights
GDET may be one of the only publicly-traded pure play covering three of the fastest growing, multi-billion-dollar, next-gen industries: Cryptocurrency, Blockchain, and CBD products. Thus, investors can participate in all 3 industries via one investment vehicle, GDET.
GDET’s new CBD products subsidiary, The Greenery, appears poised to generate meaningful revenue right out of the gate. The Company has been prepping for the receipt of inventory for its initial diversified, product run.
Given the upcoming aggressive rollout of its target marketing, Goldman Small Cap Research believes that the CBD subsidiary alone could end 2019 on a $2-3M annual revenue run-rate.
GDET’s HyperDigital Technologies subsidiary is setting the stage to secure multiple money services business licenses in order to host cryptocurrency ATM (or kiosk) units throughout the country during 2019. Once deployed, these units can generate high returns per transaction, regardless of crypto pricing changes. GDET also runs crypto mining operations in New Jersey.
An early stage player with a diversified revenue stream in high profile and high growth markets, we believe GDET offers considerable upside. As GDET achieves CBD revenue milestones along with broad cryptocurrency ATM deployment, these event-driven shares could reach the $0.06 level, a valuation similar to other high-growth, diversified emerging companies.
Market Outlook:
Despite bitcoin pulling back after a colossal run in 2017, bitcoin enthusiasts still believe the cryptocurrency will be able to hit new highs consistently during the 2nd half of this year.
The $275 billion cryptocurrency market is continuing to experience a serious rally with bitcoin flirting with $8,000 once again.
Bitcoin , as well as blockchain (a transaction ledger that maintains identical copies across each member computer within a network), is being forecast as the Next Big Thing for the future.
For an idea of just how big blockchain may become, David Marcus, a vice president at Facebook , recently said he was stepping down from the board of directors at cryptocurrency exchange Coinbase. Instead he will be leading Facebook’s blockchain strategy. When you have the biggest social media company jumping on the blockchain bandwagon, it speaks in volumes of what hopes big companies have for this arena.
In 2017, the aggregate value of crypto currencies jumped just under $600 billion
In 2017, the aggregate value of digital currencies, including bitcoin and ethereum , saw a jump of almost $600 billion, which in percentage terms was more than 3,300%. That’s a gain of 3,300% in only twelve months.
The share prices of semiconductor stocks such as NVIDIA , Advanced Micro Devices , and Taiwan Semiconductor Manufacturing Company, saw positive impacts in the last year as a result of seeing a strong demand from high performance computing like cryptocurrency mining.
(A report published by TrustNodes has revealed that Ethereum miners make almost $2.5 Billion on an annual basis!)
Famous Venture Capitalist Tim Draper once said that he thinks bitcoin will hit over $100,000. This is the man who said that Bitcoin will hit $10,000 in three years back in 2014. It hit almost $20,000 in 2017.
Draper has also responded to people questioning whether or not he will sell his bitcoin with this question: "Why would I sell the future for the past?"
CBD is being called the next Gold Rush and is expected to become a massive industry. Hemp Industry Daily projects hemp-derived CBD retail sales will surge to as much as $7.5 billion by 2023.
CBD is now being added to everything from skin cream to ice cream. It can be derived from hemp or marijuana.
GDET introduced its all new hemp derived CBD products that is for sale under the Company’s new “The Greenery” label, earlier this year.
With the legalization of hemp farming in the United States under the 2018 Farm Act recently signed into law by President Trump, GDET's CBD products are all made in the USA. The initial product line from The Greenery includes two gel caps, one oil and one salve which are all Non-GMO, Eco friendly and full spectrum.
The Company recently announced that The Greenery would also introduce a cosmeceutical and active lifestyle collection to its product line. This purchase order will include quantities of the honey hemp products, gummies, and pet wellness collection. In addition to fulfilling the new lines, several SKUs of The Greenery’s best-selling product have also been reordered including the highly-acclaimed CBD-infused hydration face mask.
GDET CEO Anil Idnani commented, “I am very proud to announce that The Greenery is ready to expand its inventory through the new purchase order of all natural CBD product. My team was able to procure these items at favorable pricing and availability, which will allow us to extend advantageous pricing to our customers as well. While we work with our supplier to get this order fulfilled, we are focused to creating the best in class website that can support the company’s expansion.”
Technical Analysis
As we mentioned above, GDET has a history of seeing rapid gains in the short term. Just last month, it hit over a penny when it was as low as $0.0055 at the end of April. The gain here was 100% in just a few days.
Earlier this year shares shares were as low as $0.0027 at the end of February and then hit $0.0229 in March for a Gain of Nearly 750% in Just a Few Weeks!
A move to $0.01 would show traders gains of up to +44.93%.
A move to $0.02 would show traders gains of up to +189.86%.
A move all the way to Goldman Small Cap Research's $0.06 target price would show traders gains of +769%!
Based on our very own chart analysis, we see the potential for a move of over +167%!
The Bottom-Line
We love these subpenny alerts because even the smallest move can result in massive gains for traders.
Based on its past history, and our research, we believe that GDET could be our next subpenny alert to run-up for triple-digit gains.
Add it to the top of your watchlist immediately.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by ACN LLC to conduct a one-day investor relations advertising and marketing campaign for GDET. We have been previously compensated fifteen thousand dollars by ACN LLC to conduct a one-day investor relations advertising and marketing campaign for GDET -which has expired. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
GDET is our new subpenny alert w/ a 6-cent price target.
=====================
GDET ( GD Entertainment & Technology, Inc.)
Alert Price: $0.0069
Chart Analysis
Goldman Price Target: $0.06
Goldman Small Cap Research Report
Website | Recent News
Ecommerce: http://www.thegreeneryco.com
========================
Members,
Earlier today we promised you an explosive subpenny alert with massive upside potential.
In case you forgot, our last subpenny alert broke out for over +230% in profits!
You'll be happy to know, that our latest subpenny alert has the potential to breakout for all that and more.
In fact, the company has an upside of +769% from today's subpenny alert price.
Please turn your immediate attention to GD Entertainment And Technology (OTC: GDET).
GDET is the Top Pure Play on 3 of the Fastest Growing Industries
GDET, focuses on high growth industries to fulfill a diverse selection of premium products nationwide. The company currently has three subsidiaries: DreamCard, HyperDigital Technologies, and The Greenery. DreamCard allows users to create a customizable debit or credit card using its state-of the-art online platform Dreamcard. cc HyperDigital Technologies is the Cryptocurrency ATM sector of GDET and aims to secure multiple MSB, money services business, licenses in order to host ATM units throughout the country. The Greenery is a new subsidiary slated to launch a broad offering of hemp-derived CBD products.
Subpenny Stocks = Big Moves
GDET has a history of seeing rapid gains in the short term. Just last month it hit over a penny when it was as low as $0.0055 at the end of April. The gain here was 100% in just a few days.
Earlier this year shares shares were as low as $0.0027 at the end of February and then hit $0.0229 in March for a Gain of Nearly 750% in Just a Few Weeks!
We are banking on another big move from GDET tomorrow, as both the crypto and cannabis sectors are heating up.
We see no reason why GDET can't once again move beyond $0.01.
Especially since the Company has recently made some big announcements that are sure to grab the attention of the Street.
At the end of last month GDET announced that it had completed its migration to a new cryptocurrency mining pool and is running at full capacity.
The new mining pool is also fully integrated with major cryptocurrency exchanges, which means the user can seamlessly send and trade the cryptocurrency reward payouts in real time market conditions. With lesser transaction and payout times/restrictions, the flexibility of converting the cryptocurrency can become more favorable.
The $275 billion cryptocurrency market is continuing to experience a serious rally with bitcoin once again moving past $8,000.
GDET CEO Anil Idnani commented, “I am very proud to announce that my team was able to complete this migration on every one of our machines without any difficulties. We are already experiencing a higher total operating hashrate than the previous mining pool our machines were integrated with. The upgrade in firmware and new mining pool allows the operation to run at full capacity during this crypto rally and I look forward to seeing what new barriers Bitcoin and cryptocurrencies break next.”
The Greenery is updating their e-commerce platform to include upgraded features such as live chat support, wholesaler login, bulk purchase + subscription order capabilities and much more. In addition to its enhanced retail content, the website will provide product education made available free to all visitors.
The Greenery has placed a purchase order for CBD product, sourced by its preferred US manufacturer. The Company recently announced that The Greenery would introduce a cosmeceutical and active lifestyle collection to its product line. This purchase order will include quantities of the honey hemp products, gummies, and pet wellness collection. In addition to fulfilling the new lines, several SKUs of The Greenery’s best-selling product have also been reordered including the highly-acclaimed CBD-infused hydration face mask.
The above actions by GDET could result in a massive influx of revenue in the very near future.
That being said, we have a feeling that GDET is going to be our next subpenny alert to deliver triple digit gains.
But don't just take our word for it, Goldman Small Cap Research recently slapped a $0.06 price target on this $0.0069 stock.
We just did the quick math, and that's an upside of over +769%!
About GD Entertainment and Technology
GD Entertainment & Technology, also known as GDET, focuses on high growth industries to fulfill a diverse selection of premium products nationwide. The company currently has three subsidiaries: DreamCard, HyperDigital Technologies, and The Greenery. DreamCard allows users to create a customizable debit or credit card using its state-of the-art online platform Dreamcard. cc HyperDigital Technologies is the Cryptocurrency ATM sector of GDET and aims to secure multiple MSB, money services business, licenses in order to host ATM units throughout the country. The Greenery is a new subsidiary slated to launch a broad offering of hemp-derived CBD products.
Company Highlights
GDET may be one of the only publicly-traded pure play covering three of the fastest growing, multi-billion-dollar, next-gen industries: Cryptocurrency, Blockchain, and CBD products. Thus, investors can participate in all 3 industries via one investment vehicle, GDET.
GDET’s new CBD products subsidiary, The Greenery, appears poised to generate meaningful revenue right out of the gate. The Company has been prepping for the receipt of inventory for its initial diversified, product run.
Given the upcoming aggressive rollout of its target marketing, Goldman Small Cap Research believes that the CBD subsidiary alone could end 2019 on a $2-3M annual revenue run-rate.
GDET’s HyperDigital Technologies subsidiary is setting the stage to secure multiple money services business licenses in order to host cryptocurrency ATM (or kiosk) units throughout the country during 2019. Once deployed, these units can generate high returns per transaction, regardless of crypto pricing changes. GDET also runs crypto mining operations in New Jersey.
An early stage player with a diversified revenue stream in high profile and high growth markets, we believe GDET offers considerable upside. As GDET achieves CBD revenue milestones along with broad cryptocurrency ATM deployment, these event-driven shares could reach the $0.06 level, a valuation similar to other high-growth, diversified emerging companies.
Market Outlook:
Despite bitcoin pulling back after a colossal run in 2017, bitcoin enthusiasts still believe the cryptocurrency will be able to hit new highs consistently during the 2nd half of this year.
The $275 billion cryptocurrency market is continuing to experience a serious rally with bitcoin flirting with $8,000 once again.
Bitcoin , as well as blockchain (a transaction ledger that maintains identical copies across each member computer within a network), is being forecast as the Next Big Thing for the future.
For an idea of just how big blockchain may become, David Marcus, a vice president at Facebook , recently said he was stepping down from the board of directors at cryptocurrency exchange Coinbase. Instead he will be leading Facebook’s blockchain strategy. When you have the biggest social media company jumping on the blockchain bandwagon, it speaks in volumes of what hopes big companies have for this arena.
In 2017, the aggregate value of crypto currencies jumped just under $600 billion
In 2017, the aggregate value of digital currencies, including bitcoin and ethereum , saw a jump of almost $600 billion, which in percentage terms was more than 3,300%. That’s a gain of 3,300% in only twelve months.
The share prices of semiconductor stocks such as NVIDIA , Advanced Micro Devices , and Taiwan Semiconductor Manufacturing Company, saw positive impacts in the last year as a result of seeing a strong demand from high performance computing like cryptocurrency mining.
(A report published by TrustNodes has revealed that Ethereum miners make almost $2.5 Billion on an annual basis!)
Famous Venture Capitalist Tim Draper once said that he thinks bitcoin will hit over $100,000. This is the man who said that Bitcoin will hit $10,000 in three years back in 2014. It hit almost $20,000 in 2017.
Draper has also responded to people questioning whether or not he will sell his bitcoin with this question: "Why would I sell the future for the past?"
CBD is being called the next Gold Rush and is expected to become a massive industry. Hemp Industry Daily projects hemp-derived CBD retail sales will surge to as much as $7.5 billion by 2023.
CBD is now being added to everything from skin cream to ice cream. It can be derived from hemp or marijuana.
GDET introduced its all new hemp derived CBD products that is for sale under the Company’s new “The Greenery” label, earlier this year.
With the legalization of hemp farming in the United States under the 2018 Farm Act recently signed into law by President Trump, GDET's CBD products are all made in the USA. The initial product line from The Greenery includes two gel caps, one oil and one salve which are all Non-GMO, Eco friendly and full spectrum.
The Company recently announced that The Greenery would also introduce a cosmeceutical and active lifestyle collection to its product line. This purchase order will include quantities of the honey hemp products, gummies, and pet wellness collection. In addition to fulfilling the new lines, several SKUs of The Greenery’s best-selling product have also been reordered including the highly-acclaimed CBD-infused hydration face mask.
GDET CEO Anil Idnani commented, “I am very proud to announce that The Greenery is ready to expand its inventory through the new purchase order of all natural CBD product. My team was able to procure these items at favorable pricing and availability, which will allow us to extend advantageous pricing to our customers as well. While we work with our supplier to get this order fulfilled, we are focused to creating the best in class website that can support the company’s expansion.”
Technical Analysis
As we mentioned above, GDET has a history of seeing rapid gains in the short term. Just last month, it hit over a penny when it was as low as $0.0055 at the end of April. The gain here was 100% in just a few days.
Earlier this year shares shares were as low as $0.0027 at the end of February and then hit $0.0229 in March for a Gain of Nearly 750% in Just a Few Weeks!
A move to $0.01 would show traders gains of up to +44.93%.
A move to $0.02 would show traders gains of up to +189.86%.
A move all the way to Goldman Small Cap Research's $0.06 target price would show traders gains of +769%!
Based on our very own chart analysis, we see the potential for a move of over +167%!
The Bottom-Line
We love these subpenny alerts because even the smallest move can result in massive gains for traders.
Based on its past history, and our research, we believe that GDET could be our next subpenny alert to run-up for triple-digit gains.
Add it to the top of your watchlist immediately.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by ACN LLC to conduct a one-day investor relations advertising and marketing campaign for GDET. We have been previously compensated fifteen thousand dollars by ACN LLC to conduct a one-day investor relations advertising and marketing campaign for GDET -which has expired. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
$SOLY Soliton Inc continue to rally higher, more expected.
June has been a fantastic month for investors in NASDAQ:SOLY which has released numerous announcements of a very positive nature regarding pipeline products with new FDA clearance.
As of this morning it has been announced that there will be a conference call today to update investors, this could move the stock considerably.
https://www.marketwatch.com/press-releas...
COMPANY PROFILE
Soliton , Inc. is a medical development company. It develops healthcare technological devices for medical and cosmetic treatments. The firm's devices generate planar acoustic waves or shock waves in cosmetic surgical procedures, aesthetic surgical procedures, and dermatology procedures for treatments. The company was founded by Walter V. Klemp & Christopher Capelli and is headquartered in Houston, TX .
$SOLY Soliton Inc continue to rally higher, more expected.
June has been a fantastic month for investors in NASDAQ:SOLY which has released numerous announcements of a very positive nature regarding pipeline products with new FDA clearance.
As of this morning it has been announced that there will be a conference call today to update investors, this could move the stock considerably.
https://www.marketwatch.com/press-releas...
COMPANY PROFILE
Soliton , Inc. is a medical development company. It develops healthcare technological devices for medical and cosmetic treatments. The firm's devices generate planar acoustic waves or shock waves in cosmetic surgical procedures, aesthetic surgical procedures, and dermatology procedures for treatments. The company was founded by Walter V. Klemp & Christopher Capelli and is headquartered in Houston, TX .
$JAGX BREAKOUT STOCK ON NEWS RELEASE
****Jaguar Health Subsidiary Receiving Preclinical Services Funded by the National Institute of Allergy and Infectious Diseases in Support of Development of Lechlemer Drug Product Candidate for Cholera Indication*******
COMPANY PROFILE
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
$JAGX BREAKOUT STOCK ON NEWS RELEASE
****Jaguar Health Subsidiary Receiving Preclinical Services Funded by the National Institute of Allergy and Infectious Diseases in Support of Development of Lechlemer Drug Product Candidate for Cholera Indication*******
COMPANY PROFILE
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
$nvfy BREAKOUT POTENTIAL ON $2 MILLION SHARE REPURCHASE
****************HOT STOCK FOR BREAKOUT ON $2 MILLION SHARE REPURCHASE ANNOUNCEMENT, MARKET cap $20MILLION.**************
COMPANY PROFILE
Nova Lifestyle, Inc. designs, markets and manufactures modern home furniture. Its collections of lifestyle furniture brands include diamond sofa, colorful world, giorgio mobili and other. The firm sells its products under the brand name, Diamond Sofa. The company was founded by Ya Ming Wong and Yuen Ching Ho in 1992 and is headquartered in Commerce, CA.
$nvfy BREAKOUT POTENTIAL ON $2 MILLION SHARE REPURCHASE
****************HOT STOCK FOR BREAKOUT ON $2 MILLION SHARE REPURCHASE ANNOUNCEMENT, MARKET cap $20MILLION.**************
COMPANY PROFILE
Nova Lifestyle, Inc. designs, markets and manufactures modern home furniture. Its collections of lifestyle furniture brands include diamond sofa, colorful world, giorgio mobili and other. The firm sells its products under the brand name, Diamond Sofa. The company was founded by Ya Ming Wong and Yuen Ching Ho in 1992 and is headquartered in Commerce, CA.
$BYND Euphoria may be about to come to a end.
It has been quite a run for BYND since its IPO but there comes a point when such euphoria and fomo comes to a sudden end. When this happens do not be left holding on for the stock to go higher again, after a 300% move it could continue to burn the shorts, but remember this is a company that sells plant based meat alternatives. Why would well established food producers not just produce their own alternative and distribute it much more economically than BYND . This products holds no unique selling point, it's not a revolutionary tech IPO and it does not deserve the value given to it by the street. We would not want to be the last man standing holding this stock when it starts to drop , it will be a cash machine for investors.
SHORT INTEREST <50%
AVERAGE ANALYSTS PRICE TARGET $103
AVERAGE ANALYSTS RECOMMENDATION HOLD
$BYND Euphoria may be about to come to a end.
It has been quite a run for BYND since its IPO but there comes a point when such euphoria and fomo comes to a sudden end. When this happens do not be left holding on for the stock to go higher again, after a 300% move it could continue to burn the shorts, but remember this is a company that sells plant based meat alternatives. Why would well established food producers not just produce their own alternative and distribute it much more economically than BYND . This products holds no unique selling point, it's not a revolutionary tech IPO and it does not deserve the value given to it by the street. We would not want to be the last man standing holding this stock when it starts to drop , it will be a cash machine for investors.
SHORT INTEREST <50%
AVERAGE ANALYSTS PRICE TARGET $103
AVERAGE ANALYSTS RECOMMENDATION HOLD
$PLAY Dave & Buster's is a Good company but Bad stock to hold.
The stock of PLAY has 10 buy ratings and 1 overweight rating but it just keeps disappointing investors, SEEMINGLY IN CORRECTION SINCE JULY 2017, and it doesn't look like it is over. The stock has been selling off in quite high volume into earnings so investors are nervous regarding results and the chart technically is very BEARISH . Having lost all support from they MA'S it looks very vulnerable to a drop out of what could be interpreted as a bear flag formation. We think any bounce in the stock will be short lived and more downside is needed, to complete the overall C wave of the correction back to the $38-$34 region.
AVERAGE ANALYSTS PRICE TARGET $63
AVERAGE ANALYSTS RECOMMENDATION BUY
SHORT INTEREST 17.44%
P/E RATIO 17.25
COMPANY PROFILE
Dave & Buster's Entertainment, Inc. is an owner and operator of entertainment and dining venues under the name Dave & Buster's. Its concept is to offer its customers the opportunity to Eat Drink Play all in one location, through a full menu of casual dining food items and a full selection of non-alcoholic and alcoholic beverage items together with an extensive assortment of entertainment attractions, including skill and sports-oriented redemption games, video games, interactive simulators and other traditional games. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Dallas, TX .
$PLAY Dave & Buster's is a Good company but Bad stock to hold.
The stock of PLAY has 10 buy ratings and 1 overweight rating but it just keeps disappointing investors, SEEMINGLY IN CORRECTION SINCE JULY 2017, and it doesn't look like it is over. The stock has been selling off in quite high volume into earnings so investors are nervous regarding results and the chart technically is very BEARISH . Having lost all support from they MA'S it looks very vulnerable to a drop out of what could be interpreted as a bear flag formation. We think any bounce in the stock will be short lived and more downside is needed, to complete the overall C wave of the correction back to the $38-$34 region.
AVERAGE ANALYSTS PRICE TARGET $63
AVERAGE ANALYSTS RECOMMENDATION BUY
SHORT INTEREST 17.44%
P/E RATIO 17.25
COMPANY PROFILE
Dave & Buster's Entertainment, Inc. is an owner and operator of entertainment and dining venues under the name Dave & Buster's. Its concept is to offer its customers the opportunity to Eat Drink Play all in one location, through a full menu of casual dining food items and a full selection of non-alcoholic and alcoholic beverage items together with an extensive assortment of entertainment attractions, including skill and sports-oriented redemption games, video games, interactive simulators and other traditional games. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Dallas, TX .
$AVGO Could Apple deal help burst resistance for Broadcom ?
Broadcom Inc disclosed Monday afternoon that it has landed a two-year deal with Apple Inc to provide some components, sending shares higher in after-hours trading. In a filing with the Securities and Exchange Commission, Broadcom said that it had agreed to supply radio-frequency components for smartphones, tablets and smartwatches, and that Apple said it intends to rely solely on Broadcom for the components as long as the company can meet commitments for quantity and quality.
Impressive as the deal may be we are just not overly confident heading into earnings as certain worries still hang over the stock in regards their recent acquisitions, the earnings call should shed light on the situation. From a technical perspective the stoch has made a great recovery from the 21% selloff but major resistance has now stopped it in its tracks. Hopefully earnings will be the catalysts to get moving towards the highs once again and closer to the Average Analysts price target of $321.
Rosenblatt Securities reiterated buy rating with $350 price target on Monday 10th June
“We see Huawei as already built in to the current share price for AVGO and reiterate our Buy rating and $350 PT into the print (Thursday, June 13 th ) on the company’s secular semiconductor prospect and FCF generation.”
$AVGO Could Apple deal help burst resistance for Broadcom ?
Broadcom Inc disclosed Monday afternoon that it has landed a two-year deal with Apple Inc to provide some components, sending shares higher in after-hours trading. In a filing with the Securities and Exchange Commission, Broadcom said that it had agreed to supply radio-frequency components for smartphones, tablets and smartwatches, and that Apple said it intends to rely solely on Broadcom for the components as long as the company can meet commitments for quantity and quality.
Impressive as the deal may be we are just not overly confident heading into earnings as certain worries still hang over the stock in regards their recent acquisitions, the earnings call should shed light on the situation. From a technical perspective the stoch has made a great recovery from the 21% selloff but major resistance has now stopped it in its tracks. Hopefully earnings will be the catalysts to get moving towards the highs once again and closer to the Average Analysts price target of $321.
Rosenblatt Securities reiterated buy rating with $350 price target on Monday 10th June
“We see Huawei as already built in to the current share price for AVGO and reiterate our Buy rating and $350 PT into the print (Thursday, June 13 th ) on the company’s secular semiconductor prospect and FCF generation.”
$HDS Earnings may provide a great entry into HD Supply
The company has a great track record and had rewarded investors long term, while also maintaining a good financial structure. Recent market weakness had resulted in a sell off which weakened they indicators, but the Momentum indicator which is a leading indicator is positive. Weakness in the economy has also added pressure on the FED to cut rates, which would be a great help to this sector. Much will depend on the earnings call tomorrow, hopefully the pessimism off others is not carried through by HDS
RECENT UPGRADE TO $53
AVERAGE ANALYSTS PRICE TARGET $48.27
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
COMPANY PROFILE
HD Supply Holdings, Inc. engages as an industrial distributors in North America. It operates through the following segments: Facilities Maintenance, Construction & Industrial and Corporate & Elimination. The Facilities Maintenance segment distributes MRO products, provides value-added services and fabricates custom products. The Construction & Industrial segment specializes in the distribution of hardware, tools, engineered materials and safety products to non-residential and residential contractors. The Corporate & Elimination segment includes costs related to centralized support functions, which are comprised of finance, information technology, human resources, legal, supply chain and other support services, and removes inter-segment transactions. The company is headquartered in Atlanta , GA.
$HDS Earnings may provide a great entry into HD Supply
The company has a great track record and had rewarded investors long term, while also maintaining a good financial structure. Recent market weakness had resulted in a sell off which weakened they indicators, but the Momentum indicator which is a leading indicator is positive. Weakness in the economy has also added pressure on the FED to cut rates, which would be a great help to this sector. Much will depend on the earnings call tomorrow, hopefully the pessimism off others is not carried through by HDS
RECENT UPGRADE TO $53
AVERAGE ANALYSTS PRICE TARGET $48.27
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
COMPANY PROFILE
HD Supply Holdings, Inc. engages as an industrial distributors in North America. It operates through the following segments: Facilities Maintenance, Construction & Industrial and Corporate & Elimination. The Facilities Maintenance segment distributes MRO products, provides value-added services and fabricates custom products. The Construction & Industrial segment specializes in the distribution of hardware, tools, engineered materials and safety products to non-residential and residential contractors. The Corporate & Elimination segment includes costs related to centralized support functions, which are comprised of finance, information technology, human resources, legal, supply chain and other support services, and removes inter-segment transactions. The company is headquartered in Atlanta , GA.
$HRB Stay on the sidelines into earnings.
UNLIKE MANY OF ITS COMPETITORS WHO ARE SOARING TO NEW HIGHS HRB IS STRUGGLING TO FIND ANY TRACTION IN THE MARKET. CURRENTLY ABOVE ITS AVERAGE ANALYSTS PRICE TARGET POST EARNINGS
A SWOON OF REGRADING COULD FOLLOW EARNINGS ON TUESDAY WHICH IS A RISKY POSITION TO BE IN.
From a technical perspective the stock is in a long term correction cycle which should have more downside, despite a golden cross recently the RSI has been in a downtrend and we think that the gap below needs filled before any positive moves higher. From a optimistic perspective there is a high short interest which could lead to quite a pop if earnings have any surprises, so we just sit and see what happens, no need to gamble on this.
AVERAGE ANALYSTS PRICE TARGET $25.72
AVERAGE ANALYSTS RECOMMENDATION HOLD
P/E RATIO 8.47
SHORT INTEREST 17%
COMPANY PROFILE
H&R Block, Inc. engages in the provision of tax preparation and other services. It offers assisted and do-it-yourself tax return preparation solutions through multiple channels and distribute the H&R block-branded financial products and services, including those of its financial partners, to the general public primarily in the United States, Canada, and Australia. The company was founded by Henry W. Bloch and Richard A. Bloch on January 25, 1955 and is headquartered in Kansas City, MO.
$HRB Stay on the sidelines into earnings.
UNLIKE MANY OF ITS COMPETITORS WHO ARE SOARING TO NEW HIGHS HRB IS STRUGGLING TO FIND ANY TRACTION IN THE MARKET. CURRENTLY ABOVE ITS AVERAGE ANALYSTS PRICE TARGET POST EARNINGS
A SWOON OF REGRADING COULD FOLLOW EARNINGS ON TUESDAY WHICH IS A RISKY POSITION TO BE IN.
From a technical perspective the stock is in a long term correction cycle which should have more downside, despite a golden cross recently the RSI has been in a downtrend and we think that the gap below needs filled before any positive moves higher. From a optimistic perspective there is a high short interest which could lead to quite a pop if earnings have any surprises, so we just sit and see what happens, no need to gamble on this.
AVERAGE ANALYSTS PRICE TARGET $25.72
AVERAGE ANALYSTS RECOMMENDATION HOLD
P/E RATIO 8.47
SHORT INTEREST 17%
COMPANY PROFILE
H&R Block, Inc. engages in the provision of tax preparation and other services. It offers assisted and do-it-yourself tax return preparation solutions through multiple channels and distribute the H&R block-branded financial products and services, including those of its financial partners, to the general public primarily in the United States, Canada, and Australia. The company was founded by Henry W. Bloch and Richard A. Bloch on January 25, 1955 and is headquartered in Kansas City, MO.
$RDFN Upgrade sparks a short term rally in Redfin
Not many investors were expecting NASDAQ:RDFN to receive any upgrades for quite a while considering the price action post earnings , but today John Campbell from Stephens upgraded the stock to Overweight from Underweight and a $23 price target. The stock has a high short interest which contributed to the 7.48% gain today, despite this we believe it will be a short lived bounce as the volume today was not that convincing. If the market becomes weak once again RDFN will soon be able to fill the gap created below.
AVERAGE ANALYSTS PRICE TARGET $21.38
AVERAGE ANALYSTS RECOMMENDATION HOLD
SHORT INTEREST 22.43%
ANALYSTS UPGRADE COMMENTS
"We are upgrading RDFN to Overweight from Underweight and raising our price target to $23 (up from $18). We have come to better appreciate RDFN's market position/strategy and a handful of its newer offerings," Campbell said.
"We also believe that the Company is beginning to lay the groundwork for a more e-commerce type offering (Redfin Direct, Redfin Now, packaged ancillary services, etc.). In addition, we see a very favorable NT set up as the stock has dropped into a more enticing valuation/buying window, many of its top markets are in the process of recovering from a tough 2H18 fallout and we see improved operating results moving forward, starting with impressive 2Q19 results. Lastly, we believe that RDFN has the type of model that can thrive in today's real estate ecosystem or one that is dramatically altered (ex. lower commission rates, limited buyer's agent involvement, etc.), " the analyst added.
COMPANY PROFILE
Redfin Corp. is a technology-powered residential real estate brokerage, which engages in buying and selling homes. It operates through the following segments: Real Estate, Properties and Other. The Real Estate segment revenue is derived from commissions and fees charged on real estate services transactions. The Properties segment revenue is earned when the Company sells homes that it previously bought directly from homeowners. The Other segment revenue includes fees earned from mortgage banking services, title settlement services, Walk Score data services and advertising. The company was founded by David Selinger, David Eraker, and Michael Dougherty in 2004 and is headquartered in Seattle, WA.
$RDFN Upgrade sparks a short term rally in Redfin
Not many investors were expecting NASDAQ:RDFN to receive any upgrades for quite a while considering the price action post earnings , but today John Campbell from Stephens upgraded the stock to Overweight from Underweight and a $23 price target. The stock has a high short interest which contributed to the 7.48% gain today, despite this we believe it will be a short lived bounce as the volume today was not that convincing. If the market becomes weak once again RDFN will soon be able to fill the gap created below.
AVERAGE ANALYSTS PRICE TARGET $21.38
AVERAGE ANALYSTS RECOMMENDATION HOLD
SHORT INTEREST 22.43%
ANALYSTS UPGRADE COMMENTS
"We are upgrading RDFN to Overweight from Underweight and raising our price target to $23 (up from $18). We have come to better appreciate RDFN's market position/strategy and a handful of its newer offerings," Campbell said.
"We also believe that the Company is beginning to lay the groundwork for a more e-commerce type offering (Redfin Direct, Redfin Now, packaged ancillary services, etc.). In addition, we see a very favorable NT set up as the stock has dropped into a more enticing valuation/buying window, many of its top markets are in the process of recovering from a tough 2H18 fallout and we see improved operating results moving forward, starting with impressive 2Q19 results. Lastly, we believe that RDFN has the type of model that can thrive in today's real estate ecosystem or one that is dramatically altered (ex. lower commission rates, limited buyer's agent involvement, etc.), " the analyst added.
COMPANY PROFILE
Redfin Corp. is a technology-powered residential real estate brokerage, which engages in buying and selling homes. It operates through the following segments: Real Estate, Properties and Other. The Real Estate segment revenue is derived from commissions and fees charged on real estate services transactions. The Properties segment revenue is earned when the Company sells homes that it previously bought directly from homeowners. The Other segment revenue includes fees earned from mortgage banking services, title settlement services, Walk Score data services and advertising. The company was founded by David Selinger, David Eraker, and Michael Dougherty in 2004 and is headquartered in Seattle, WA.
Add $SPEX to the top of your watchlist, Low Float Stock Alert
=====================
SPEX ( Spherix Incorporated)
Float: 1.98M
Alert Price: $2.97
CEO Interview
Chart Analysis
Website | Recent News
========================
Add SPEX to the top of your watchlist. See why this low-float alert could be the Nasdaq's top gainer
Members,
Earlier today we told you that we had a fresh low-float, Nasdaq listed opportunity on our radar.
Now we ask that you please put your immediate attention on SPEX ( Spherix Incorporated).
This technology development company committed to the fostering of innovative ideas is shaping up to be one of our most exciting growth plays of 2019!
SPEX is Developing Game-Changing Drugs for the Treatment of Pancreatic Cancer & Leaukemia
Just a few weeks ago, on May 16th, SPEX announced the terms of an Asset Purchase Agreement with CBM BioPharma.
SPEX “purchased substantially all of CBM's assets including, among other things, a license agreement, university contracts, and contracts with a Chief Scientific Officer, as well as a Scientific advisory board.”
Here’s a little about the company’s new investment:
CBM is a privately held pharmaceutical company with exclusive drug development rights from world-renowned partners including Wake Forest Innovations and the University of Texas at Austin.
CBM has a team of leading drug development scientists who will be joining Spherix as advisors to advance the technology.
The CBM platform focuses on the treatment of numerous cancers, including acute myeloid leukemia ( AML ), acute lymphoblastic leukemia (ALL), and pancreatic cancer.
Two specific proprietary drugs that are currently being researched are:
KPC34 (Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia”
DHA-dFdC (Pancreatic Cancer Drug)”
KPC34 “is a next generation treatment” that “has also been shown to be more effective in AML relapse cases” and “has served to double the mean survival time of patients versus the current standard of care treatments.”
Click here of a must see video on KPC34
According to the Leukemia & Lymphoma Society, “there are an estimated 399,967 people living with or in remission from leukemia in the US” and “in 2019, 61,780 people are expected to be diagnosed with leukemia.”
DHA-dFdC, the company’s second drug, “has shown positive results in preclinical studies, inhibiting pancreatic tumor growth” and “also overcomes tumor cell resistance to current chemotherapeutic drugs.”
Pancreatic cancer is set to become the second leading cause of cancer-related deaths in the US in 2020 after lung cancer.
There is a huge need for innovation and improvement to address these serious diseases.
Plus, recently the company announced that their Preclinical Pancreatic Cancer Treatment Study will be Moving Forward.
The global treatment costs for both these diseases are in the multi-billions and continue to grow.
Given SPEX’s prior successes, they could be best suited to help advance these key projects to market and provide help to those suffering.
SPEX also released the following info that is sure to grab the attention of the Street
The Company has total assets of $11,937,000.
The Company has liabilities of $982,000.
A snapshot of a data point for sure, but compelling, confidence inspiring statistics that reflect a risk-taker of a company with interests in a myriad of lucrative verticals which cashed in big on one of its earliest investments, dropping two million shares into the proforma when an early stage investment IPO'd and a hypothetical windfall became an actual one.
The asset/liability ratio alone should raise Spherix's street cred above other companies in any of its targeted industries where blue sky optimism and 'someday' dialogue too often suffice in lieu of real asset gains or profits.
But perhaps what is most compelling when considered in the context of this stirring asset/liability chasm is another singular number:
The Company has 2,010,074 shares of common stock outstanding.
Nearly $12 million in assets as of the last Q, just under a million in debt, and roughly 2 million shares in play. Post that snippet on your favorite stock message board and see what the natives say.
We'll let the reader do the math on their own as the share price changes daily, but it's more than a little interesting to consider Spherix's present and future simply going by the numbers.
Source: https://www.accesswire.com/547900/StockL......
About Spherix
Spherix Incorporated is a technology development company committed to the fostering of innovative ideas. Spherix Incorporated was formed in 1967 as a scientific research company.
Their activities generally include the acquisition and development of technology through internal or external research and development. In addition, they seek to acquire existing rights to intellectual property through the acquisition of already issued patents and pending patent applications, both in the United States and abroad. They may alone, or in conjunction with others, develop products and processes associated with technology development and monetizing related intellectual property.
Company Highlights:
Spherix Reports First Quarter 2019 Results of $11,937,000 in Assets and $982,000 in Liabilities
Company filed its Form-10Q for the period ended March 31, 2019, which showed total assets of $11,937,000.00 and liabilities of $982,000.00, with 2,010,074 shares of common stock outstanding.
In addition, the Company announced a restructuring of the terms of its proposed merger with CBM BioPharma, Inc. ( CBM ), a Delaware corporation. In lieu of the previously announced merger, the Company announced the terms of an Asset Purchase Agreement with CBM , whereby the Company purchased substantially all of CBM's assets including, among other things, a license agreement, university contracts, and contracts with a Chief Scientific Officer, as well as a Scientific advisory board. The revised agreement is significantly less dilutive to Spherix shareholders, as Spherix is paying $8,000,000.00 to CBM in total compensation, as opposed to the previously announced $16,500,000.00, as more fully set forth in the Company's filings. The acquisition of CBM's assets is pending shareholder approval.
In addition, the Company announced that it purchased a 20% shareholder's stake in CBM along with certain interests in DatChat, Inc. Spherix was successful in acquiring these interests in CBM at a substantial discount to CBM's valuation. The 20% shareholder stake in CBM will give Spherix the ability to participate in any dividends declared by CBM in the future.
Mr. Anthony Hayes, CEO of Spherix stated, "The revised negotiated terms with CBM BioPharma in the Asset Purchase Agreement will introduce valuable assets into the Spherix family. The new agreement will be less dilutive to Spherix shareholders. I am also pleased to note that CBM has received some early, favorable correspondence from the Patent Office about its University of Texas patent applications. We will provide additional information as it comes available, but it is certainly a positive development for CBM ."
"Post-closing, Spherix shareholders will still own a majority interest in the Company. Further, Spherix's 20% ownership in CBM is an accretive benefit to Spherix shareholders and by having an ownership interest in CBM , Spherix will participate in any dividend distributions made by CBM in the future. This may include cash dividends that might result from the future sale of Spherix stock. We look forward to sharing additional information with our shareholders about the proposed asset purchase in the upcoming weeks through both investor outreach and our upcoming SEC filings."
Market Outlook:
Pancreatic cancer is set to become the second leading cause of cancer-related deaths in the US in 2020 after lung cancer.
The global pancreatic cancer treatment market size was valued at USD 1.7 billion in 2015. The rising prevalence of obesity, alcohol consumption, and smoking is expected to propel the market growth.
According to the Leukemia & Lymphoma Society, “there are an estimated 399,967 people living with or in remission from leukemia in the US” and “in 2019, 61,780 people are expected to be diagnosed with leukemia.”
The Global Leukemia Therapeutic Market is expected to exceed more than US$ 12.50 Billion by 2024 at a CAGR of 4% in the given forecast period.
There is a huge need for innovation and improvement to address these serious diseases.
Technical Analysis
Like all low-float alerts, SPEX has the potential to run-up big on volume .
The chart looks extremely attractive at the moment.
The price appears to have consolidated, and is now in the apex with an explosive move higher impending.
Its retrace appears complete, and looks to have developed strong support at these levels.
Bases on our very own chart analysis, we see the potential for a move of over +70%!
The Bottom-Line
SPEX looks like a winner in both the financial and technical sides.
This should be the only ticker on your radar tomorrow.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by World Wide Holdings LLC to conduct a one-day investor relations advertising and marketing campaign for SPEX . Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Add $SPEX to the top of your watchlist, Low Float Stock Alert
=====================
SPEX ( Spherix Incorporated)
Float: 1.98M
Alert Price: $2.97
CEO Interview
Chart Analysis
Website | Recent News
========================
Add SPEX to the top of your watchlist. See why this low-float alert could be the Nasdaq's top gainer
Members,
Earlier today we told you that we had a fresh low-float, Nasdaq listed opportunity on our radar.
Now we ask that you please put your immediate attention on SPEX ( Spherix Incorporated).
This technology development company committed to the fostering of innovative ideas is shaping up to be one of our most exciting growth plays of 2019!
SPEX is Developing Game-Changing Drugs for the Treatment of Pancreatic Cancer & Leaukemia
Just a few weeks ago, on May 16th, SPEX announced the terms of an Asset Purchase Agreement with CBM BioPharma.
SPEX “purchased substantially all of CBM's assets including, among other things, a license agreement, university contracts, and contracts with a Chief Scientific Officer, as well as a Scientific advisory board.”
Here’s a little about the company’s new investment:
CBM is a privately held pharmaceutical company with exclusive drug development rights from world-renowned partners including Wake Forest Innovations and the University of Texas at Austin.
CBM has a team of leading drug development scientists who will be joining Spherix as advisors to advance the technology.
The CBM platform focuses on the treatment of numerous cancers, including acute myeloid leukemia ( AML ), acute lymphoblastic leukemia (ALL), and pancreatic cancer.
Two specific proprietary drugs that are currently being researched are:
KPC34 (Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia”
DHA-dFdC (Pancreatic Cancer Drug)”
KPC34 “is a next generation treatment” that “has also been shown to be more effective in AML relapse cases” and “has served to double the mean survival time of patients versus the current standard of care treatments.”
Click here of a must see video on KPC34
According to the Leukemia & Lymphoma Society, “there are an estimated 399,967 people living with or in remission from leukemia in the US” and “in 2019, 61,780 people are expected to be diagnosed with leukemia.”
DHA-dFdC, the company’s second drug, “has shown positive results in preclinical studies, inhibiting pancreatic tumor growth” and “also overcomes tumor cell resistance to current chemotherapeutic drugs.”
Pancreatic cancer is set to become the second leading cause of cancer-related deaths in the US in 2020 after lung cancer.
There is a huge need for innovation and improvement to address these serious diseases.
Plus, recently the company announced that their Preclinical Pancreatic Cancer Treatment Study will be Moving Forward.
The global treatment costs for both these diseases are in the multi-billions and continue to grow.
Given SPEX’s prior successes, they could be best suited to help advance these key projects to market and provide help to those suffering.
SPEX also released the following info that is sure to grab the attention of the Street
The Company has total assets of $11,937,000.
The Company has liabilities of $982,000.
A snapshot of a data point for sure, but compelling, confidence inspiring statistics that reflect a risk-taker of a company with interests in a myriad of lucrative verticals which cashed in big on one of its earliest investments, dropping two million shares into the proforma when an early stage investment IPO'd and a hypothetical windfall became an actual one.
The asset/liability ratio alone should raise Spherix's street cred above other companies in any of its targeted industries where blue sky optimism and 'someday' dialogue too often suffice in lieu of real asset gains or profits.
But perhaps what is most compelling when considered in the context of this stirring asset/liability chasm is another singular number:
The Company has 2,010,074 shares of common stock outstanding.
Nearly $12 million in assets as of the last Q, just under a million in debt, and roughly 2 million shares in play. Post that snippet on your favorite stock message board and see what the natives say.
We'll let the reader do the math on their own as the share price changes daily, but it's more than a little interesting to consider Spherix's present and future simply going by the numbers.
Source: https://www.accesswire.com/547900/StockL......
About Spherix
Spherix Incorporated is a technology development company committed to the fostering of innovative ideas. Spherix Incorporated was formed in 1967 as a scientific research company.
Their activities generally include the acquisition and development of technology through internal or external research and development. In addition, they seek to acquire existing rights to intellectual property through the acquisition of already issued patents and pending patent applications, both in the United States and abroad. They may alone, or in conjunction with others, develop products and processes associated with technology development and monetizing related intellectual property.
Company Highlights:
Spherix Reports First Quarter 2019 Results of $11,937,000 in Assets and $982,000 in Liabilities
Company filed its Form-10Q for the period ended March 31, 2019, which showed total assets of $11,937,000.00 and liabilities of $982,000.00, with 2,010,074 shares of common stock outstanding.
In addition, the Company announced a restructuring of the terms of its proposed merger with CBM BioPharma, Inc. ( CBM ), a Delaware corporation. In lieu of the previously announced merger, the Company announced the terms of an Asset Purchase Agreement with CBM , whereby the Company purchased substantially all of CBM's assets including, among other things, a license agreement, university contracts, and contracts with a Chief Scientific Officer, as well as a Scientific advisory board. The revised agreement is significantly less dilutive to Spherix shareholders, as Spherix is paying $8,000,000.00 to CBM in total compensation, as opposed to the previously announced $16,500,000.00, as more fully set forth in the Company's filings. The acquisition of CBM's assets is pending shareholder approval.
In addition, the Company announced that it purchased a 20% shareholder's stake in CBM along with certain interests in DatChat, Inc. Spherix was successful in acquiring these interests in CBM at a substantial discount to CBM's valuation. The 20% shareholder stake in CBM will give Spherix the ability to participate in any dividends declared by CBM in the future.
Mr. Anthony Hayes, CEO of Spherix stated, "The revised negotiated terms with CBM BioPharma in the Asset Purchase Agreement will introduce valuable assets into the Spherix family. The new agreement will be less dilutive to Spherix shareholders. I am also pleased to note that CBM has received some early, favorable correspondence from the Patent Office about its University of Texas patent applications. We will provide additional information as it comes available, but it is certainly a positive development for CBM ."
"Post-closing, Spherix shareholders will still own a majority interest in the Company. Further, Spherix's 20% ownership in CBM is an accretive benefit to Spherix shareholders and by having an ownership interest in CBM , Spherix will participate in any dividend distributions made by CBM in the future. This may include cash dividends that might result from the future sale of Spherix stock. We look forward to sharing additional information with our shareholders about the proposed asset purchase in the upcoming weeks through both investor outreach and our upcoming SEC filings."
Market Outlook:
Pancreatic cancer is set to become the second leading cause of cancer-related deaths in the US in 2020 after lung cancer.
The global pancreatic cancer treatment market size was valued at USD 1.7 billion in 2015. The rising prevalence of obesity, alcohol consumption, and smoking is expected to propel the market growth.
According to the Leukemia & Lymphoma Society, “there are an estimated 399,967 people living with or in remission from leukemia in the US” and “in 2019, 61,780 people are expected to be diagnosed with leukemia.”
The Global Leukemia Therapeutic Market is expected to exceed more than US$ 12.50 Billion by 2024 at a CAGR of 4% in the given forecast period.
There is a huge need for innovation and improvement to address these serious diseases.
Technical Analysis
Like all low-float alerts, SPEX has the potential to run-up big on volume .
The chart looks extremely attractive at the moment.
The price appears to have consolidated, and is now in the apex with an explosive move higher impending.
Its retrace appears complete, and looks to have developed strong support at these levels.
Bases on our very own chart analysis, we see the potential for a move of over +70%!
The Bottom-Line
SPEX looks like a winner in both the financial and technical sides.
This should be the only ticker on your radar tomorrow.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by World Wide Holdings LLC to conduct a one-day investor relations advertising and marketing campaign for SPEX . Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
$CASY MAJOR CHANGES AT CASEY'S STORES, BREAKOUT POTENTIAL
There has been a lot of very positive changes at NASDAQ:CASY in the past few weeks, the updated digital store and online ordering system now offers easier ordering, more customisation and faster carryout which is hoped to improve efficiency and boost sales. More recently Casey's have appointed former IHOP CEO Darren Rebelez to the CEO role, he brings 25 years of business leadership experience.
H.LYNN Horak commented
“Darren brings a remarkable combination of leadership experience in the convenience store, fuel and restaurant industries, and he has an impressive track record of driving performance and innovation. We have enjoyed getting to know Darren through our succession planning process and are confident that he will build on Casey’s strong heritage of customer service, employee development, giving back to our communities, and our focus on creating sustainable growth and profitability.”
From a technical perspective the stock is looking like a breakout candidate, currently forming a ascending triangle and holding support above all MA'S, all the indicators are also in tension and signal a substantial move ahead, hopefully that is a break up not down. $upside alert for $137 and breakdown short alert on $128
AVERAGE ANALYSTS PRICE TARGET $139
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
P/E RATIO 25
COMPANY PROFILE
Casey's General Stores, Inc. engages in the management and operation of convenience stores and gasoline stations. It offers food, beverages, tobacco products, health and beauty aids, automotive products, and other nonfood items. The company was founded by Donald F. Lamberti in 1959 and is headquartered in Ankeny, IA.
$CASY MAJOR CHANGES AT CASEY'S STORES, BREAKOUT POTENTIAL
There has been a lot of very positive changes at NASDAQ:CASY in the past few weeks, the updated digital store and online ordering system now offers easier ordering, more customisation and faster carryout which is hoped to improve efficiency and boost sales. More recently Casey's have appointed former IHOP CEO Darren Rebelez to the CEO role, he brings 25 years of business leadership experience.
H.LYNN Horak commented
“Darren brings a remarkable combination of leadership experience in the convenience store, fuel and restaurant industries, and he has an impressive track record of driving performance and innovation. We have enjoyed getting to know Darren through our succession planning process and are confident that he will build on Casey’s strong heritage of customer service, employee development, giving back to our communities, and our focus on creating sustainable growth and profitability.”
From a technical perspective the stock is looking like a breakout candidate, currently forming a ascending triangle and holding support above all MA'S, all the indicators are also in tension and signal a substantial move ahead, hopefully that is a break up not down. $upside alert for $137 and breakdown short alert on $128
AVERAGE ANALYSTS PRICE TARGET $139
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
P/E RATIO 25
COMPANY PROFILE
Casey's General Stores, Inc. engages in the management and operation of convenience stores and gasoline stations. It offers food, beverages, tobacco products, health and beauty aids, automotive products, and other nonfood items. The company was founded by Donald F. Lamberti in 1959 and is headquartered in Ankeny, IA.
Add $SPEX to the top of your watchlist, Low Float Stock Alert
SPEX ( Spherix Incorporated)
Float: 1.98M
Alert Price: $2.97
CEO Interview
Chart Analysis
Website | Recent News
========================
Add SPEX to the top of your watchlist. See why this low-float alert could be the Nasdaq's top gainer
Members,
Earlier today we told you that we had a fresh low-float, Nasdaq listed opportunity on our radar.
Now we ask that you please put your immediate attention on SPEX ( Spherix Incorporated).
This technology development company committed to the fostering of innovative ideas is shaping up to be one of our most exciting growth plays of 2019!
SPEX is Developing Game-Changing Drugs for the Treatment of Pancreatic Cancer & Leaukemia
Just a few weeks ago, on May 16th, SPEX announced the terms of an Asset Purchase Agreement with CBM BioPharma.
SPEX “purchased substantially all of CBM's assets including, among other things, a license agreement, university contracts, and contracts with a Chief Scientific Officer, as well as a Scientific advisory board.”
Here’s a little about the company’s new investment:
CBM is a privately held pharmaceutical company with exclusive drug development rights from world-renowned partners including Wake Forest Innovations and the University of Texas at Austin.
CBM has a team of leading drug development scientists who will be joining Spherix as advisors to advance the technology.
The CBM platform focuses on the treatment of numerous cancers, including acute myeloid leukemia ( AML ), acute lymphoblastic leukemia (ALL), and pancreatic cancer.
Two specific proprietary drugs that are currently being researched are:
KPC34 (Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia”
DHA-dFdC (Pancreatic Cancer Drug)”
KPC34 “is a next generation treatment” that “has also been shown to be more effective in AML relapse cases” and “has served to double the mean survival time of patients versus the current standard of care treatments.”
Click here of a must see video on KPC34
According to the Leukemia & Lymphoma Society, “there are an estimated 399,967 people living with or in remission from leukemia in the US” and “in 2019, 61,780 people are expected to be diagnosed with leukemia.”
DHA-dFdC, the company’s second drug, “has shown positive results in preclinical studies, inhibiting pancreatic tumor growth” and “also overcomes tumor cell resistance to current chemotherapeutic drugs.”
Pancreatic cancer is set to become the second leading cause of cancer-related deaths in the US in 2020 after lung cancer.
There is a huge need for innovation and improvement to address these serious diseases.
Plus, recently the company announced that their Preclinical Pancreatic Cancer Treatment Study will be Moving Forward.
The global treatment costs for both these diseases are in the multi-billions and continue to grow.
Given SPEX’s prior successes, they could be best suited to help advance these key projects to market and provide help to those suffering.
SPEX also released the following info that is sure to grab the attention of the Street
The Company has total assets of $11,937,000.
The Company has liabilities of $982,000.
A snapshot of a data point for sure, but compelling, confidence inspiring statistics that reflect a risk-taker of a company with interests in a myriad of lucrative verticals which cashed in big on one of its earliest investments, dropping two million shares into the proforma when an early stage investment IPO'd and a hypothetical windfall became an actual one.
The asset/liability ratio alone should raise Spherix's street cred above other companies in any of its targeted industries where blue sky optimism and 'someday' dialogue too often suffice in lieu of real asset gains or profits.
But perhaps what is most compelling when considered in the context of this stirring asset/liability chasm is another singular number:
The Company has 2,010,074 shares of common stock outstanding.
Nearly $12 million in assets as of the last Q, just under a million in debt, and roughly 2 million shares in play. Post that snippet on your favorite stock message board and see what the natives say.
We'll let the reader do the math on their own as the share price changes daily, but it's more than a little interesting to consider Spherix's present and future simply going by the numbers.
Source: https://www.accesswire.com/547900/StockL...
About Spherix
Spherix Incorporated is a technology development company committed to the fostering of innovative ideas. Spherix Incorporated was formed in 1967 as a scientific research company.
Their activities generally include the acquisition and development of technology through internal or external research and development. In addition, they seek to acquire existing rights to intellectual property through the acquisition of already issued patents and pending patent applications, both in the United States and abroad. They may alone, or in conjunction with others, develop products and processes associated with technology development and monetizing related intellectual property.
Company Highlights:
Spherix Reports First Quarter 2019 Results of $11,937,000 in Assets and $982,000 in Liabilities
Company filed its Form-10Q for the period ended March 31, 2019, which showed total assets of $11,937,000.00 and liabilities of $982,000.00, with 2,010,074 shares of common stock outstanding.
In addition, the Company announced a restructuring of the terms of its proposed merger with CBM BioPharma, Inc. ( CBM ), a Delaware corporation. In lieu of the previously announced merger, the Company announced the terms of an Asset Purchase Agreement with CBM , whereby the Company purchased substantially all of CBM's assets including, among other things, a license agreement, university contracts, and contracts with a Chief Scientific Officer, as well as a Scientific advisory board. The revised agreement is significantly less dilutive to Spherix shareholders, as Spherix is paying $8,000,000.00 to CBM in total compensation, as opposed to the previously announced $16,500,000.00, as more fully set forth in the Company's filings. The acquisition of CBM's assets is pending shareholder approval.
In addition, the Company announced that it purchased a 20% shareholder's stake in CBM along with certain interests in DatChat, Inc. Spherix was successful in acquiring these interests in CBM at a substantial discount to CBM's valuation. The 20% shareholder stake in CBM will give Spherix the ability to participate in any dividends declared by CBM in the future.
Mr. Anthony Hayes, CEO of Spherix stated, "The revised negotiated terms with CBM BioPharma in the Asset Purchase Agreement will introduce valuable assets into the Spherix family. The new agreement will be less dilutive to Spherix shareholders. I am also pleased to note that CBM has received some early, favorable correspondence from the Patent Office about its University of Texas patent applications. We will provide additional information as it comes available, but it is certainly a positive development for CBM ."
"Post-closing, Spherix shareholders will still own a majority interest in the Company. Further, Spherix's 20% ownership in CBM is an accretive benefit to Spherix shareholders and by having an ownership interest in CBM , Spherix will participate in any dividend distributions made by CBM in the future. This may include cash dividends that might result from the future sale of Spherix stock. We look forward to sharing additional information with our shareholders about the proposed asset purchase in the upcoming weeks through both investor outreach and our upcoming SEC filings."
Market Outlook:
Pancreatic cancer is set to become the second leading cause of cancer-related deaths in the US in 2020 after lung cancer.
The global pancreatic cancer treatment market size was valued at USD 1.7 billion in 2015. The rising prevalence of obesity, alcohol consumption, and smoking is expected to propel the market growth.
According to the Leukemia & Lymphoma Society, “there are an estimated 399,967 people living with or in remission from leukemia in the US” and “in 2019, 61,780 people are expected to be diagnosed with leukemia.”
The Global Leukemia Therapeutic Market is expected to exceed more than US$ 12.50 Billion by 2024 at a CAGR of 4% in the given forecast period.
There is a huge need for innovation and improvement to address these serious diseases.
Technical Analysis
Like all low-float alerts, SPEX has the potential to run-up big on volume .
The chart looks extremely attractive at the moment.
The price appears to have consolidated, and is now in the apex with an explosive move higher impending.
Its retrace appears complete, and looks to have developed strong support at these levels.
Bases on our very own chart analysis, we see the potential for a move of over +70%!
The Bottom-Line
SPEX looks like a winner in both the financial and technical sides.
This should be the only ticker on your radar tomorrow.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by World Wide Holdings LLC to conduct a one-day investor relations advertising and marketing campaign for SPEX . Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Add $SPEX to the top of your watchlist, Low Float Stock Alert
SPEX ( Spherix Incorporated)
Float: 1.98M
Alert Price: $2.97
CEO Interview
Chart Analysis
Website | Recent News
========================
Add SPEX to the top of your watchlist. See why this low-float alert could be the Nasdaq's top gainer
Members,
Earlier today we told you that we had a fresh low-float, Nasdaq listed opportunity on our radar.
Now we ask that you please put your immediate attention on SPEX ( Spherix Incorporated).
This technology development company committed to the fostering of innovative ideas is shaping up to be one of our most exciting growth plays of 2019!
SPEX is Developing Game-Changing Drugs for the Treatment of Pancreatic Cancer & Leaukemia
Just a few weeks ago, on May 16th, SPEX announced the terms of an Asset Purchase Agreement with CBM BioPharma.
SPEX “purchased substantially all of CBM's assets including, among other things, a license agreement, university contracts, and contracts with a Chief Scientific Officer, as well as a Scientific advisory board.”
Here’s a little about the company’s new investment:
CBM is a privately held pharmaceutical company with exclusive drug development rights from world-renowned partners including Wake Forest Innovations and the University of Texas at Austin.
CBM has a team of leading drug development scientists who will be joining Spherix as advisors to advance the technology.
The CBM platform focuses on the treatment of numerous cancers, including acute myeloid leukemia ( AML ), acute lymphoblastic leukemia (ALL), and pancreatic cancer.
Two specific proprietary drugs that are currently being researched are:
KPC34 (Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia”
DHA-dFdC (Pancreatic Cancer Drug)”
KPC34 “is a next generation treatment” that “has also been shown to be more effective in AML relapse cases” and “has served to double the mean survival time of patients versus the current standard of care treatments.”
Click here of a must see video on KPC34
According to the Leukemia & Lymphoma Society, “there are an estimated 399,967 people living with or in remission from leukemia in the US” and “in 2019, 61,780 people are expected to be diagnosed with leukemia.”
DHA-dFdC, the company’s second drug, “has shown positive results in preclinical studies, inhibiting pancreatic tumor growth” and “also overcomes tumor cell resistance to current chemotherapeutic drugs.”
Pancreatic cancer is set to become the second leading cause of cancer-related deaths in the US in 2020 after lung cancer.
There is a huge need for innovation and improvement to address these serious diseases.
Plus, recently the company announced that their Preclinical Pancreatic Cancer Treatment Study will be Moving Forward.
The global treatment costs for both these diseases are in the multi-billions and continue to grow.
Given SPEX’s prior successes, they could be best suited to help advance these key projects to market and provide help to those suffering.
SPEX also released the following info that is sure to grab the attention of the Street
The Company has total assets of $11,937,000.
The Company has liabilities of $982,000.
A snapshot of a data point for sure, but compelling, confidence inspiring statistics that reflect a risk-taker of a company with interests in a myriad of lucrative verticals which cashed in big on one of its earliest investments, dropping two million shares into the proforma when an early stage investment IPO'd and a hypothetical windfall became an actual one.
The asset/liability ratio alone should raise Spherix's street cred above other companies in any of its targeted industries where blue sky optimism and 'someday' dialogue too often suffice in lieu of real asset gains or profits.
But perhaps what is most compelling when considered in the context of this stirring asset/liability chasm is another singular number:
The Company has 2,010,074 shares of common stock outstanding.
Nearly $12 million in assets as of the last Q, just under a million in debt, and roughly 2 million shares in play. Post that snippet on your favorite stock message board and see what the natives say.
We'll let the reader do the math on their own as the share price changes daily, but it's more than a little interesting to consider Spherix's present and future simply going by the numbers.
Source: https://www.accesswire.com/547900/StockL...
About Spherix
Spherix Incorporated is a technology development company committed to the fostering of innovative ideas. Spherix Incorporated was formed in 1967 as a scientific research company.
Their activities generally include the acquisition and development of technology through internal or external research and development. In addition, they seek to acquire existing rights to intellectual property through the acquisition of already issued patents and pending patent applications, both in the United States and abroad. They may alone, or in conjunction with others, develop products and processes associated with technology development and monetizing related intellectual property.
Company Highlights:
Spherix Reports First Quarter 2019 Results of $11,937,000 in Assets and $982,000 in Liabilities
Company filed its Form-10Q for the period ended March 31, 2019, which showed total assets of $11,937,000.00 and liabilities of $982,000.00, with 2,010,074 shares of common stock outstanding.
In addition, the Company announced a restructuring of the terms of its proposed merger with CBM BioPharma, Inc. ( CBM ), a Delaware corporation. In lieu of the previously announced merger, the Company announced the terms of an Asset Purchase Agreement with CBM , whereby the Company purchased substantially all of CBM's assets including, among other things, a license agreement, university contracts, and contracts with a Chief Scientific Officer, as well as a Scientific advisory board. The revised agreement is significantly less dilutive to Spherix shareholders, as Spherix is paying $8,000,000.00 to CBM in total compensation, as opposed to the previously announced $16,500,000.00, as more fully set forth in the Company's filings. The acquisition of CBM's assets is pending shareholder approval.
In addition, the Company announced that it purchased a 20% shareholder's stake in CBM along with certain interests in DatChat, Inc. Spherix was successful in acquiring these interests in CBM at a substantial discount to CBM's valuation. The 20% shareholder stake in CBM will give Spherix the ability to participate in any dividends declared by CBM in the future.
Mr. Anthony Hayes, CEO of Spherix stated, "The revised negotiated terms with CBM BioPharma in the Asset Purchase Agreement will introduce valuable assets into the Spherix family. The new agreement will be less dilutive to Spherix shareholders. I am also pleased to note that CBM has received some early, favorable correspondence from the Patent Office about its University of Texas patent applications. We will provide additional information as it comes available, but it is certainly a positive development for CBM ."
"Post-closing, Spherix shareholders will still own a majority interest in the Company. Further, Spherix's 20% ownership in CBM is an accretive benefit to Spherix shareholders and by having an ownership interest in CBM , Spherix will participate in any dividend distributions made by CBM in the future. This may include cash dividends that might result from the future sale of Spherix stock. We look forward to sharing additional information with our shareholders about the proposed asset purchase in the upcoming weeks through both investor outreach and our upcoming SEC filings."
Market Outlook:
Pancreatic cancer is set to become the second leading cause of cancer-related deaths in the US in 2020 after lung cancer.
The global pancreatic cancer treatment market size was valued at USD 1.7 billion in 2015. The rising prevalence of obesity, alcohol consumption, and smoking is expected to propel the market growth.
According to the Leukemia & Lymphoma Society, “there are an estimated 399,967 people living with or in remission from leukemia in the US” and “in 2019, 61,780 people are expected to be diagnosed with leukemia.”
The Global Leukemia Therapeutic Market is expected to exceed more than US$ 12.50 Billion by 2024 at a CAGR of 4% in the given forecast period.
There is a huge need for innovation and improvement to address these serious diseases.
Technical Analysis
Like all low-float alerts, SPEX has the potential to run-up big on volume .
The chart looks extremely attractive at the moment.
The price appears to have consolidated, and is now in the apex with an explosive move higher impending.
Its retrace appears complete, and looks to have developed strong support at these levels.
Bases on our very own chart analysis, we see the potential for a move of over +70%!
The Bottom-Line
SPEX looks like a winner in both the financial and technical sides.
This should be the only ticker on your radar tomorrow.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by World Wide Holdings LLC to conduct a one-day investor relations advertising and marketing campaign for SPEX . Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
$LTC LITECOIN showing great strength . Bullish
Litecoin continues to show great strength and resilience as it tries to break the $122 resistance level . Indicators remain strong and in particular the MOMentum which has now reset and going higher in a strong move, this is often seen as a very good leading indicator. Volume has also remained strong with bulls stepping in on any weakness, once again the weekly close should some bring some volatility and a push towards the top of the bollinger band would be very positive. Any move above above $122 we will consider adding to our position, while sub $100 is a sell area.
$LTC LITECOIN showing great strength . Bullish
Litecoin continues to show great strength and resilience as it tries to break the $122 resistance level . Indicators remain strong and in particular the MOMentum which has now reset and going higher in a strong move, this is often seen as a very good leading indicator. Volume has also remained strong with bulls stepping in on any weakness, once again the weekly close should some bring some volatility and a push towards the top of the bollinger band would be very positive. Any move above above $122 we will consider adding to our position, while sub $100 is a sell area.
$KMX Carmax is in the sweet spot of Retail. Bullish
Earnings are approaching and NYSE:KMX is one of the sweet spots in retail. New car sales are declining which limits the supply of second hand cars , this in turn increases demand and prices in the second hand market, improving margins and earnings . The same can be said for parts suppliers etc as cars are been maintained for longer. The chart illustrates just how good the sector is, the price is about to bang heads with the ATH level once again and earnings may be the stimulus to get past that level. Set alert for break above $82.
AVERAGE ANALYSTS PRICE TARGET $83
AVERAGE ANALYSTS RECOMMENDATION BUY
P/E RATIO 16
COMPANY PROFILE
CarMax , Inc. is as a holding company, which engages in the retail of used vehicles and wholesale vehicle auction operator. It operates through the CarMax Sales Operations and CarMax Auto Finance (CAF) business segments. The CarMax Sales Operations segment consists of all aspects of its auto merchandising and service operations. The CAF segment provides vehicle financing to customers buying retail vehicles. The company was founded by Richard L. Sharp and William Austin Ligon in September 1993 and is headquartered in Richmond, VA .
$KMX Carmax is in the sweet spot of Retail. Bullish
Earnings are approaching and NYSE:KMX is one of the sweet spots in retail. New car sales are declining which limits the supply of second hand cars , this in turn increases demand and prices in the second hand market, improving margins and earnings . The same can be said for parts suppliers etc as cars are been maintained for longer. The chart illustrates just how good the sector is, the price is about to bang heads with the ATH level once again and earnings may be the stimulus to get past that level. Set alert for break above $82.
AVERAGE ANALYSTS PRICE TARGET $83
AVERAGE ANALYSTS RECOMMENDATION BUY
P/E RATIO 16
COMPANY PROFILE
CarMax , Inc. is as a holding company, which engages in the retail of used vehicles and wholesale vehicle auction operator. It operates through the CarMax Sales Operations and CarMax Auto Finance (CAF) business segments. The CarMax Sales Operations segment consists of all aspects of its auto merchandising and service operations. The CAF segment provides vehicle financing to customers buying retail vehicles. The company was founded by Richard L. Sharp and William Austin Ligon in September 1993 and is headquartered in Richmond, VA .